Janumet 50/1000 mg Tablet

Janumet 50/1000mg tablet is an antidiabetic medicine used for treating type 2 diabetes mellitus. It contains two active ingredients: Sitagliptin (50mg) + Metformin (1000mg). Sitagliptin (50mg) belongs to the group class of DPP-4 inhibitors and Metformin biguanide class belongs to the biguanide class. They help combine blood sugar levels in people with type 2 diabetes mellitus by improving insulin action and reducing glucose production in the body. A doctor's prescription is required to ensure safe and effective treatment.

• Control blood sugar in a diabetic patient.

Every medication shows various side effects. Janumet 50/1000mg tablet also causes various symptoms, some are mild, and some need proper medical attention to reduce the side effects. Reach out to a doctor if any of the symptoms persist or worsen:

• Low blood sugar (Hypoglycaemia)
• Lightheadedness
• Dizziness
• Anxiety
• Nervousness
• Tiredness
• Feeling hungry
• Visual disturbances
• Headache
• Shaking
• Sweating
• Pale skin
• Skin rashes
• Pain, redness, swelling at the injection site.

Janumet 50/1000mg tablet should be taken with a meal to avoid stomach upset. It should be taken twice daily at the fixed time every day to enhance the effectiveness of the medication. Never self-administer the dose, and if you miss a dose, do not take a double dose to make up for the missed one. Always follow the prescription-based medication to avoid complications during the treatment.

Janumet 50/1000mg tablet works by decreasing glucose production in the liver, reducing absorption of glucose, and improving insulin sensitivity. Sitagliptin increases the level of incretin hormones that help the pancreas release more insulin after meals and reduce the amount of glucose produced by the liver. Together, they improve blood sugar more effectively than either medication alone.

• Bhagyasri, A., Raja, I., Panwar, B., Duggani, M., Nagalla, B., Prabhu, M. U., & Kaktikar, S. Digital Nutrition Counseling and its Impact on Diabetics and Prediabetic Individuals in the Developing Country. https://www.informaticsjournals.co.in/index.php/fijrfn/citationstylelanguage/get/apa?submissionId=44790&publicationId=46187
• Akhtar, J., Khan, M. I., Parveen, S., & Ahmad, A. An update on fixed‐dose combination of SGLT‐2 and DPP‐4 inhibitors in the management of type‐2 diabetes. https://www.researchgate.net/publication/372892117_An_Update_On_Fixed-Dose_Combination_Of_Sglt-2_And_Dpp-4_Inhibitors_In_The_Management_Of_Type-2_Diabetes_Section_A-Research_paper_Eur
• Wavrin, A. M. (2019). Risks and Benefits of Statin Use When at Target Goal. https://pmc.ncbi.nlm.nih.gov/articles/PMC10892755/
• Hantash, A. A., Safieh, M. A., Iriqat, S., & Daraghmeh, M. (2021). Bilateral Abducens Nerve Palsy and the possible Association with COVID-19: A Case Report. J. Archives of Medical Case Reports and Case Study, 4(4). https://auctoresonline.org/article/bilateral-abducens-nerve-palsy-and-the-possible-association-with-covid-19-a-case-report https://auctoresonline.org/article/bilateral-abducens-nerve-palsy-and-the-possible-association-with-covid-19-a-case-report
• Gowan, J., & Roller, L. (2016). Disease state management: Diabetes type 2: Improving control by working collaboratively. AJP: The Australian Journal of Pharmacy, 97(1152), 78-86. https://ajp.com.au/cpd/disease-state-management/ https://ajp.com.au/cpd/disease-state-management/